doxorubicin + cyclophosphamide + paclitaxel + carboplatin

The drug combination "doxorubicin + cyclophosphamide + paclitaxel + carboplatin" is a chemotherapy regimen used primarily in the treatment of breast cancer. This combination includes four distinct anticancer drugs that work through different mechanisms to target cancer cells. **Composition and Mechanism** This regimen combines: 1. **Doxorubicin (Adriamycin)** - An anthracycline that damages DNA inside cancer cells, preventing them from dividing and causing them to die. 2. **Cyclophosphamide (Cytoxan)** - An alkylating agent that attaches to and damages DNA in cancer cells during their resting phase, stopping cell division and slowing tumor growth. 3. **Paclitaxel (Taxol)** - A taxane that damages the structural "skeleton" supporting cancer cells (microtubules), preventing them from growing and dividing. 4. **Carboplatin** - A platinum-based chemotherapy that works similarly to other platinum compounds by interfering with DNA replication. **Administration and Schedule** While the exact administration schedule can vary, this combination may be given in different sequences: - Sometimes paclitaxel and carboplatin are given together, followed by doxorubicin and cyclophosphamide. - In other cases, doxorubicin and cyclophosphamide (AC) are given first, followed by paclitaxel (T). The sequence of administration is important, as it can affect both efficacy and toxicity. **Clinical Use** This combination is primarily used in breast cancer treatment, particularly for: - Locally advanced breast cancer - Early breast cancer - HER2-positive breast cancer (often with additional targeted therapies) The regimen has shown effectiveness in improving disease response and overall survival rates. **Side Effects** Common side effects may include: - Neutropenia (low white blood cell count) - Emesis (vomiting) - Mucositis (inflammation of the mucous membranes) - Alopecia (hair loss) - Cardiotoxicity (heart damage) - Anemia **Variations** There are several variations of this combination therapy, including: - Different dosing schedules (weekly vs. every three weeks) - Dose-dense schedules (treatments given more frequently) - Addition of targeted therapies for specific breast cancer subtypes (like trastuzumab for HER2-positive cancers) - Substitution of docetaxel for paclitaxel in some regimens The specific combination and schedule are typically determined based on the patient's cancer type, stage, and individual health factors.

Brand names

AdriamycinCytoxanTaxol

Other names

Leo W. Jenkins Cancer Center TNBC regimenNeoadjuvant Metronomic Chemotherapy for TNBC